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Patients (or Materials) and Methods: New insulin analogue AKR 
of a potential long-acting feature was evaluated in the Institute of 
Biotechnology and Antibiotics. Bioactivity of AKR was compared 
with that of USP human insulin standard in bioassays on cells and 
rabbits, while the pharmacodynamic activity on rats was referred to 
control group received 0.9% NaCl. The 3T3-L1 cells differentiated 
into adipocytes were used for the performance of insulin dependent 
glucose uptake experiment. Dose-response relationship of log insu-
lin concentration and Deoxy-D-glucose uptake of AKR was deter-
mined. The biological activity on animals was assessed on 24 albino 
rabbits according to US Pharmacopeia. The glucose concentrations 
were measured with spectrophotometer in 2 time points (1.0 and 
2.5 hours) after administration of 1 U and 2 U of insulin. Potency 
of AKR was calculated with 95% CI. Pharmacodynamic effect was 
based on glucose concentration measurement in rats with hypergly-
cemia induced by streptozotocin. The overall glycemic profile up to 
36 hours was evaluated after subcutaneous single dosing at range 
2.5 to 10.0 U/kg b.w. In the 28-day multiple dose study, AKR was 
administered twice a day at dose 5.0 U/kg b.w.
Results: Percentage of maximum Deoxy-D-glucose uptake in 3T3-
L1 cells was similar for AKR and human insulin, except the highest 
concentration in which the hook effect was observed. The absolute 
potency of a new analogue determined in rabbits was 23.94 U/mg, 
and the potency ratio of AKR versus the insulin standard was 0.90. 
The relative potency was 38.35 U/mL with confidence limit of 32.99–
44.42 U/mL. The experiment on rats confirmed with a statistical 
significance (P < 0.05) hypoglycemic activity of AKR in comparison 
of control group both after single and multiple doses. Characteristics 
for AKR profile was rather fast beginning of action (0.5-1.0 hour) 
with the maximal effect at 6 hours postdose and quite prolonged 
return to initial values. The glucose levels were stable during 4-week 
administration.
Conclusion: Bioactivity of the novel insulin analogue AKR, con-
nected with glucose metabolism was confirmed in both in vitro and in 
vivo conditions. AKR is a candidate for a hypoglycemic drug product 
in diabetes care.
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Introduction: Current acute myocardial infarction (AMI) guidelines 
recommend the use of platelet aggregation inhibitors, beta-blockers, 
angiotensin-converting enzyme inhibitors (ACEI), or angiotensin II 
receptor blockers (ARB) and statins for in-hospital and long-term 
treatment. The aim of the study was to evaluate the changes in the 
prescription of these drugs in Estonian hospitals in 2001 versus 2007 
and in 2007 versus 2011.
Patients (or Materials) and Methods: We performed a retrospective 
cross-sectional study including random samples of hospitalized AMI 
cases. Chi-square test and logistic regression were used to study the 
changes in the prescription of the drugs.
Results: Final analysis included 423 cases in 2001, 687 cases in 2007, 
and 740 cases in 2011. The prescription rates of most drugs recom-
mended for in-hospital and for out-patient use improved (Table). 
Compared with 2001, in 2007 and 2011, more patients were pre-
scribed drugs from all 5 drug (sub)groups during hospitalization 
(3.3% vs 18.5% vs 26.5%; P < 0.001) and for outpatient use (3.8% 
vs 22.2% vs 33.1%; P < 0.001). In multivariate analysis, < 75-year-
old patients and those hospitalized into a tertiary care hospital were 
more likely to be prescribed drugs from all 5 drug (sub)groups.
Conclusion: Prescription of recommended drugs for AMI patients 
increased continuously during last years in Estonia. Continuous edu-
cation programs and future studies should focus to differences of 
drug utilization in tertiary and nontertiary hospitals, also to different 
patient subgroups (ie, elderly).
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Introduction: There are potential conflicts between authorities and 
companies to fund new premium-priced drugs, especially where 
there are safety and/ or budget concerns. Dabigatran exemplifies 
these issues due to variable drug concentrations, no known antidote, 
dependence on renal elimination, and considerably more expensive 
than warfarin. The latter is a concern with the growing prevalence 
of atrial fibrillation (AF). There are also issues with potentially 
re-designing anticoagulant services. As a result, there is a need to 
review authority activities regarding dabigatran and use the findings 
to develop new models to better manage the entry of new drugs in 
the future.
Patients (or Materials) and Methods: Descriptive review and 
appraisal of educational and other activities regarding dabigatran 
pre- to postlaunch in a systematic manner among > 30 European 
countries and regions. The findings were used to develop a new model 
Table. Prescription rates of recommended drugs in Estonia.
Year 2001 Year 2007
P 2001 vs 
2007 Year 2011
P 2007 vs 
2011
During hospitalization n = 423 n = 687 n = 740
Aspirin 87.7 90.1 0.212 88.5 0.333
P2Y12 inhibitors 8.5 34.8 < 0.001 42.3 0.004
Beta-blockers 77.8 80.1 0.363 76.2 0.080
ACEI/ARB 53.7 68.3 < 0.001 63.5 0.059
Statins 16.1 48.5 < 0.001 58.0 < 0.001
Outpatient use n = 344 n = 514 n = 473
Aspirin 82.6 88.5 0.013 92.0 0.069
P2Y12 inhibitors 9.9 41.1 < 0.001 52.9 < 0.001
Beta-blockers 70.1 80.4 0.001 82.9 0.307
ACEI/ARB 52.6 73.7 < 0.001 75.9 0.434
Statins 23.5 57.6 < 0.001 72.3 < 0.001
